A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
This study is a phase 1/3 study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination with Lenalidomide and Dexamethasone in Patients with Refractory or Relapsed Multiple Myeloma
Refractory or Relapsed Multiple Myeloma
BIOLOGICAL: CT-P44(Daratumumab)|BIOLOGICAL: Darzalex Faspro(Daratumumab)
PK equivalence of CT-P44 and Darzalex Faspro, AUCWeek0-1 and AUCWeek8-10 of daratumumab., Week 0 ~ Week 24|Therapeutic equivalence of CT-P44 and Darzalex Faspro, Proportion of patients who will achieve VGPR or better (sCR + CR + VGPR) based on the confirmed BOR., Week 0 ~ Week 24
This study is a phase 1/3 study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination with Lenalidomide and Dexamethasone in Patients with Refractory or Relapsed Multiple Myeloma